Lexeo Therapeutics
LXEO
54 hedge funds and large institutions have $362M invested in Lexeo Therapeutics in 2024 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 17 increasing their positions, 6 reducing their positions, and 5 closing their positions.
460% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 5
183% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 6
74% more funds holding
Funds holding: 31 → 54 (+23)
66% more capital invested
Capital invested by funds: $217M → $362M (+$144M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
25.96% more ownership
Funds ownership: 60.73% → 86.69% (+26%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$20.7M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$20.7M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$10.3M |
| 4 |
Millennium Management
New York
|
+$8.6M |
| 5 |
BlackRock
New York
|
+$7.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.01M |
| 2 |
Citigroup
New York
|
-$668K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$459K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$346K |
| 5 |
Legal & General Group
London,
United Kingdom
|
-$221K |
LXEO Hedge Fund Activity: Q1 2024 in Review
54 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Lexeo Therapeutics (LXEO) for Q1 2024, worth a combined $362M — up 66% from $217M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new LXEO positions and 5 closed out — a net gain of 23 holders — while 17 added to existing stakes and 6 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $20.7M. The largest seller was Verition Fund Management, cutting an estimated $2.01M.
- 54 institutional investors held Lexeo Therapeutics (LXEO) as of Q1 2024, up from 31 in Q4 2023.
- Funds reported $362M of Lexeo Therapeutics stock for Q1 2024, up 66% quarter-over-quarter.
- 28 funds opened new Lexeo Therapeutics positions in Q1 2024 and 5 closed out, a net change of +23 holders.
- The largest Lexeo Therapeutics buyer in Q1 2024 was Adage Capital Partners, an estimated $20.7M added.
- The largest Lexeo Therapeutics seller in Q1 2024 was Verition Fund Management, an estimated $2.01M sold.
Based on aggregated 13F filings for Q1 2024.